As EMT and cell survival are closely related with drug resistance, we examined the effects of miR-644a and its target CTBP1 on drug sensitization, and observed that overexpression of miR-644a sensitized different breast cancer cells representing different subtypes to both chemotherapy and targeted therapy agents e.g. tamoxifen and gefitinib. Here, CTBP1 is linked to breast cancer.